On December 30, 2025, Ascendis Pharma A/S closed a warrant exercise window, resulting in a capital increase of nominal DKK 282,197, with the issuance of 282,197 ordinary shares at approximately USD $63.34 per share, raising the company’s share capital to nominal DKK 61,977,408.